Hemostasis Products Market Regional Analysis:
North American Market Insights
North America industry is likely to account for largest revenue share of 31% by 2035, owing to rising incidence of heart diseases such as heart attacks and heart strokes along with rising geriatric population in the region.According to the Centers for Disease Control and Prevention, heart disease is a major cause of death in United States, and nearly 697,000 Americans died of heart disease in 2020. Moreover, the higher healthcare spending, increasing government initiatives, favorable reimbursement policies along with presence of major market players in the market are expected to drive regional market during the forecast period.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of hemostasis products is assessed at USD 2.3 billion.
The global hemostasis products market size was valued at over USD 2.19 billion in 2025 and is expected to expand at a CAGR of around 5.6%, surpassing USD 3.78 billion revenue by 2035.
The North America hemostasis products market will secure around 31% share by 2035, driven by the rising incidence of heart diseases, the aging population, and favorable healthcare policies.
Key players in the market include Terumo Corporation, Baxter International, Inc., Sysmex Asia Pacific Pte Ltd, Abbott Healthcare Private Limited, csl behring llc, Grifols, S.A., Dexur Inc, Pfizer Inc., Tricol Biomedical., Medtronic plc.
